Evidence map›Paper›PMID 31090233›Full record

ArticleJournal of neuroscience research2019

The impact of postsynaptic density 95 blocking peptide (Tat-NR2B9c) and an iNOS inhibitor (1400W) on proteomic profile of the hippocampus in C57BL/6J mouse model of kainate-induced epileptogenesis.

Karen Tse, Dean Hammond, Deborah Simpson, Robert J Beynon, Edward Beamer, Michael Tymianski, Michael W Salter, Graeme J Sills, Thimmasettappa Thippeswamy

Open access · greenAbstract read
In one paragraph

Article in Journal of neuroscience research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. In Focus: Disease promoters during epileptogenesis.Journal of neuroscience research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Karen TseDepartment of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
Dean HammondDepartment of Molecular and Cellular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Deborah SimpsonCentre for Proteome Research, Institute of Integrative Biology, University of Liverpool, Liverpool, UK.
Robert J BeynonCentre for Proteome Research, Institute of Integrative Biology, University of Liverpool, Liverpool, UK.
Edward BeamerDepartment of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
Michael TymianskiDepartment of Physiology and Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.
Michael W SalterDepartment of Physiology and Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.
Graeme J SillsDepartment of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Thimmasettappa ThippeswamyDepartment of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.ORCID 0000-0002-9326-1896
University of Liverpool · GBUniversity of Toronto · CA

Funding

Toxin-specific and symptomatic drugs in combination with novel neuroprotectants effectively counteract DFP-induced long-term neurotoxicityR21NS099007 · NINDS · IOWA STATE UNIVERSITY · PI THIPPESWAMY, THIMMASETTAPPA · 2017 to 2018
$396k
Medical Research Council MR/M009114/1NINDS NIH HHS R21 NS099007
6 · The paper itself

Abstract

Antiepileptogenic agents that prevent the development of epilepsy following a brain insult remain the holy grail of epilepsy therapeutics. We have employed a label-free proteomic approach that allows quantification of large numbers of brain-expressed proteins in a single analysis in the mouse (male C57BL/6J) kainate (KA) model of epileptogenesis. In addition, we have incorporated two putative antiepileptogenic drugs, postsynaptic density protein-95 blocking peptide (PSD95BP or Tat-NR2B9c) and a highly selective inducible nitric oxide synthase inhibitor, 1400W, to give an insight into how such agents might ameliorate epileptogenesis. The test drugs were administered after the induction of status epilepticus (SE) and the animals were euthanized at 7 days, their hippocampi removed, and subjected to LC-MS/MS analysis. A total of 2,579 proteins were identified; their normalized abundance was compared between treatment groups using ANOVA, with correction for multiple testing by false discovery rate. Significantly altered proteins were subjected to gene ontology and KEGG pathway enrichment analyses. KA-induced SE was most robustly associated with an alteration in the abundance of proteins involved in neuroinflammation, including heat shock protein beta-1 (HSP27), glial fibrillary acidic protein, and CD44 antigen. Treatment with PSD95BP or 1400W moderated the abundance of several of these proteins plus that of secretogranin and Src substrate cortactin. Pathway analysis identified the glutamatergic synapse as a key target for both drugs. Our observations require validation in a larger-scale investigation, with candidate proteins explored in more detail. Nevertheless, this study has identified several mechanisms by which epilepsy might develop and several targets for novel drug development. OPEN PRACTICES: This article has been awarded Open Data. All materials and data are publicly accessible as supporting information. Learn more about the Open Practices badges from the Center for Open Science: https://osf.io/tvyxz/wiki.

Indexed as

AmidinesAnimalsAnticonvulsantsBenzylaminesEpilepsyHippocampusKainic AcidMaleMice, Inbred C57BLNitric Oxide Synthase Type IIPeptidesProteomicsStatus EpilepticusAmidinesAnticonvulsantsBenzylaminesKainic AcidN-(3-(aminomethyl)benzyl)acetamidineNitric Oxide Synthase Type IINos2 protein, mousePeptidesTat-NR2B9cdisease modificationglutamatergic synapseinducible nitric oxide synthase (iNOS)neuroinflammationpostsynaptic density

Identifiers

PMID31090233
PMCPMC6752963
OpenAlexW2946123909

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.